

Tuberculosis poses serious risk for patients with diabetes




Protect your patients from tuberculosis with preferred blood-based screening

A connection between diabetes and tuberculosis (TB) has long been acknowledged. Diabetes and pre-diabetes are a major health problem in the US, and after some gains, rates of TB infection are once again rising.¹

While there are many factors that make patients with diabetes particularly susceptible to TB, immune complications make treating TB in these patients difficult.

The risk of tuberculosis is **2-3 times higher for patients with diabetes**, and diabetes doubles the risk of death or poor outcomes during TB treatment²⁻⁴



38.1 million US adults—**nearly 15%**—have diabetes⁶

Patients who have TB and diabetes are at greater risk of more severe TB disease and adverse TB treatment outcomes compared to those without diabetes^{1,5}

TB Risk

Diagnosed diabetes

The risk of TB disease is **significantly elevated** in people with diabetes—ie, about

▲ 2-3x higher

No diabetes

Diabetes increases the risk that latent tuberculosis infection (LTBI) will **progress to active pulmonary TB**¹



Approximately

13M

people in the US are believed to **carry latent TB infection**⁷

Know when you should test for TB infection

Reduce the risk of future complications

Quest Diagnostics is the only national commercial reference lab to offer a choice of TB blood tests.

Your Quest representative can help you decide which TB blood test may best serve your practice. Either option includes additional advantages from Quest, including broad health plan coverage, access to a single-tube draw option, and easy test ordering and tracking through our Quanum® Lab Services Manager with EHR integration.

| Test name | Test code | CPT® codes* |
|---|-----------|-------------|
| T-SPOT®.TB | 37737 | 86481 |
| QuantIFERON®-TB Gold Plus, 1 Tube | 36970 | 86480 |
| QuantIFERON®-TB Gold Plus, 4 Tubes, Draw Site Incubated | 36971 | 86480 |

You may help prevent the development of TB in your patients with diabetes by actively screening for and treating TB infection.

Compared to the century-old Mantoux skin test, TB testing with an IGRA blood test requires just 1 tube, 1 draw, and 1 visit, which can save providers and patients time and help identify TB quickly and easily.

- Blood-based IGRA testing is highly accurate and provides objective results, with a low rate of false positives^{7,8}
- IGRA testing is preferred in all cases by the CDC, ATS, and IDSA^{7,8}



TB is strongly influenced by social and economic determinants and health-related risk factors.⁹⁻¹²
Particularly at risk are those who are

- Immigrants
- Indigent
- Immunocompromised



For more information on TB IGRA testing, contact your Quest Diagnostics sales representative or visit QuestDiagnostics.com/TBBloodTest

References

1. Ngo MD, Bartlett S, Ronacher K. Diabetes-associated susceptibility to tuberculosis: contribution of hyperglycemia vs. dyslipidemia. *Microorganisms*. 2021;9(11):2282. doi:10.3390/microorganisms9112282

2. van Crevel R, Critchley JA. The Interaction of diabetes and tuberculosis: translating research to policy and practice. *Trop Med Infect Dis*. 2021;6(1):8. doi:10.3390/tropicalmed6010008

3. CDC. Tuberculosis (TB): TB risk and people with diabetes. April 22, 2024. Accessed November 4, 2024. <https://www.cdc.gov/tb/topic/basics/tband-diabetes.html>

4. Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O, Boima V, Dey ID. The bidirectional relationship between tuberculosis and diabetes. *Tuberc Res Treat*. 2017;2017:1702578. doi:10.1155/2017/1702578

5. Abbas U, Masood KI, Khan A, et al. Tuberculosis and diabetes mellitus: relating immune impact of co-morbidity with challenges in disease management in high burden countries. *J Clin Tuberc Other Mycobact Dis*. 2022;29:100343. doi:10.1016/j.jctube.2022.100343

6. CDC. National Diabetes Statistics Report. May 15, 2024. Accessed November 2024. <https://www.cdc.gov/diabetes/php/data-research/index.html>

7. CDC. Latent tuberculosis infection: a guide for primary health care providers. April 2024. Publication # 22-0468. Accessed November 4, 2024. <https://www.cdc.gov/tb/media/pdfs/Latent-TB-Infection-A-Guide-for-Primary-Health-Care-Providers.pdf>

8. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; CDC. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection—United States, 2010. *MMWR Recomm Rep*. 2010;59(RR05):1-25. Accessed November 8, 2024. <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm>

9. US Preventive Services Task Force. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2023;329(17):1487-1494. doi:10.1001/jama.2023.4899

10. WHO. Global Tuberculosis Report, 2021. Section 6.3 TB determinants. Accessed July 15, 2024. <https://www.who.int/publications/digital/global-tuberculosis-report-2021/uhc-tb-determinants/determinants>

11. CDC. Dialysis safety. Guidelines, recommendations and resources. January 21, 2024. Accessed July 26, 2024. <https://www.cdc.gov/dialysis-safety/hcp/recommendations-resources/index.html>

12. CDC. Immigrant and refugee health. *Tuberculosis*. Published July 25, 2024. Accessed July 26, 2024. <https://www.cdc.gov/immigrant-refugee-health/hcp/domestic-guidance/tuberculosis.html>

Image content features models and is intended for illustrative purposes only.

*The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

QuestDiagnostics.com

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. © 2024 Quest Diagnostics Incorporated. All rights reserved. SB13428 11/2024